Tyra Biosciences Q2 FY26 net loss widens to $45.56 million; R&D expenses climb to $39.2 million

• Tyra Biosciences posted a Q2 net loss of $45.6 million, widening from $28.1 million a year earlier; loss per share deepened to $0.69 from $0.47.
• R&D expense climbed 61.27% to $39.2 million, while G&A rose 38.01% to $9.8 million.
• Cash, cash equivalents and marketable securities totaled $353.9 million at June 30, with runway expected into the second half of 2028.
• Initial Phase 2 results from SURF302 are expected in September, covering safety in more than 40 patients and efficacy in more than 20.
• BEACH301 safety-sentinel readout is now expected at end of Q1 2027, while the achondroplasia study opened a fifth dose level at 0.625 mg/kg.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tyra Biosciences Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202608041605PR_NEWS_USPR_____LA18882) on August 04, 2026, and is solely responsible for the information contained therein.